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Summary: The course of plasma catalytic activities of total creatine kinäse, creatine kinase isoenzyme MB,
total, cytoplasmatic and mitochondrial aspartate aminotransferase, alanine aminotransferase, lactate dehy-
drogenase, -hydroxybutyrate dehydrogenase, glutamate dehydrogenase and concentrations of myoglobin,
urea, acidic cti-glycoprotein and creatinine were followed in 33 patients suffering from acute myocardial
infarction. All patients were randomized in a double-blind, prospective study. One group (18 patients) was
infused with streptokinase 1.5 x 106 units/90 minutes; the control group received routine continuous i. v.
heparin treatment (1000 units/h). Ten hours after completion of the study protocol, treatment of both groups
of patients was continued with heparin, 1000 units/h and Aspisol®, l g/day2). Streptokinase treatment induced
earlier wash-out and therefore earlier peak levels of several enzymes: total creatine kinase (11 hours), crea-
tine kinase isoenzyme MB (6 hours), total and cytoplasmatic aspartate aminotransferase (6 hours) and lactate
dehydrogenase (9 hours). Total creatine kinase peak catalytic activity and myoglobin peak concentration were
higher in the group receiving thrombolytic therapy. A signiflcantly different course of catalytic activity be-
tween both treatment groups was found for total creatine kinase and creatine kinase isoenzyme MB, total and
cytosolic aspartate aminotransferase, lactate dehydrogenase and -hydroxybutyrate dehydrogenase. The
course of mitochondrial aspartate aminotransferase catalytic activity was different only 12 hours after the
beginning of treatmeot The shift of several catalytic activities to an earlier peak level in plasma may indicate
reperfusion of ischaemie myocardium due to thrombolytic therapy.
Systemische Kurzzeitlyse mit hochdosierter Streptokinase bei Patienten mit akutem Myokardinfarkt:
Verlauf der biochemischen Kenngrößen
Zusammenfassung: Im Rahmen einer prospektiven Doppelblindstudie mit Streptokinase (1,5 x l O6 Einhei-
ten/90 Minuten) gegenüber der Kontrolle (1000 Einheiten Heparin/Stunde als Dauerinfusion) bei Patienten
mit frischen Myokardiöfärkt wurde der zeitliche Verlauf folgender Analyte ausgewertet: Gesamt-Kreatinki-
}) This report contains essential parts of the dissertation of K. D. Kempf.
:) l g Aspisol« (Bayer) contains 900 mg D,L-lysine mono(acetylsalicylic acid) (equivalent to 500 mg acctylsalicylic acid) and 100 mg
aminoacetic acid.
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nase und Kreatinkinase-Isoenzym-MB, Gesamt-, cytoplasmatische und mitochondriale Aspartat-Amino-
transferase, Alanin-Aminotransferase, Lactatdehydrogenase, -Hydroxybutyratdehydrogenase und Gluta-
matdehydrogenase sowie Myoglobin, Harnstoff, saures cti-Glycoprotein und Kreatinin im Plasma. Alle Pa-
tienten hatten randomisiert entweder Streptokinase (18 Personen) oder Heparin (15 Personen) erhalten. Die
maximalen katalytischen Aktivitäten wurden in der Streptokinasegruppe bei der Gesamt-Kreatinkinase 11
Stunden, dem Kreatinkinase-Isoenzym-MB 6 Stunden, der Gesamt- und cytoplasmatischen Aspartat-Ami-
notransferase 6 Stunden und Lactatdehydrogenase 9 Stunden früher erreicht als in der Kontrollgruppe. Die
maximale katalytische Aktivität der Gesamt-Kreatinkinase und die maximale Konzentration des Myoglobins
waren im Plasma der mit Streptokinase behandelten Gruppe erhöht. Der zeitliche Verlauf der katalytischen
Aktivitäten der Gesamt-Kreatinkinase und der Kreatinkinase-Isoenzym-MB, der Gesamt-, cytoplasmati-
schen und teilweise auch der mitochondrialen Aspartat-Aminotransferase, der Lactatdehydrogenase und a-
Hydroxybutyratdehydrogenase war in beiden Gruppen unterschiedlich. Die Verschiebung des Peaks der ka^
talytischen Aktivitäten der Gesamt-Kreatinkinase und der Kreatinkinase-Isoenzym-MB zu einem früheren
Zeitpunkt hin könnte sich zur Beurteilung der Wirkung der Streptokinase-Therapie eignen.
Introduction
The laboratory diagnosis of myocardial infarction
usually involves measurement of total creatine ki-
nase (EC 2.7.3.2) and total lactate dehydrogenase
(EC 1.1.1.27) catalytic activities and evaluation of
their isoenzyme fractions (1). Diagnostic criteria
vary but it is generally agreed that a significant ele-
vation of creatine kinase isoenzyme MB catalytic ao
tivity accompanied by a concomitant rise in lactate
dehydrogenase isoenzyme l or total aspartate ami-
notransferase catalytic activity is pathognomonic of
acute myocardial infarction (2).
Other indicators of an evolving myocardial infarc-
tion include a rise in plasma myoglobin concentra^·
tion (3), in plasma urea concentration (4) reflecting
the degradation of protein and in plasma concentra-
tion of the acidic arglycoprotein (5), an acute-phase
reactant indicating muscle cell reparation (6).
Aspartate aminotransferase (EC 2.6.1.1) consists of
two isoenzymes, one associated with the cytoplasma
and the other with mitochondria (7). Since aspartate
aminotransferase is mainly found in striated muscles,
myocardium and liver, an increase in serum catalytic
activity correlates with diseases of these organs (8,
9). The ratio of serum mitochondrial to total serum
aspartate aminotransferase catalytic activity has
been reported to reflect the severity of cellular dam-
age (9, 10).
Modern medical treatment of acute myocardial in-
farction is preferentially aimed at the jeopardized
myocardium surrounding the fully infarcted area.
Therapeutic aims are: Decrease of CVconsumption
and increase of O2-supply of the myocardial regions
at risk. Besides analgesia, sedation, application of ß-
blocking drugs (11) and proteins such äs hyaluroni-
dase (12), decrease of preload and afterload, an ear-
ly restoration of coronary blood flow by thromboly-
sis seems to be promising (13, 14, 15).
Since acute results of thrombolytic treatment by in-
travenous application of streptokinase were not con-
troljed by coronary angiography, we were interested
to see if biochemical parameters would indicate a
possible reperfusion of ischaemic myocardium.
Methods
33 patients (31cJ, 2$) with acute myocardial infarction were se-
lected for this study. All patients with the following characteristics
were excluded: reinfarction; age over 65 yeärs; onset of infarction
Symptoms more than 6 hours before; creatine kinase catalytic ac-
tivity higher than 150 U/l; previous oral anticoagulation thefapy;
haemorrhagic diathesis; duodenal or gastric ulcer; ulcerative coli^
tis; aortic aneurism; hypertension with systolic values higher than
200 mm Hg and diastolic values higher than 120 mm Hg; apo-
plexy; Status after reanimation; traunia or Operation (more than
10 days before); metastatic diseases; bacterial endocarditis; preg-
riancy; pace maker and valvular insufficiency with continuous (ar-
rhythmia. Fouf to six weeks after the myocardial infarction, coro-
nary angiograms and scintigrams were obtained from all patients.
These data will not be available until the end of the stüdy.
In the double-blind randomized trial the patients received 1.5 x
106 units streptqkinase (Behring Institute, D-355 Marburg) in 90
minutes or 1000 units heparin per hour. Ten hours after termina-
tion of lysis, treatment of all patients was continued with 1000
units heparin per hour i. v. and l g Aspisol® per day.
Blood samples were drawn iminediately before treatment, 1.5, 3
hours and then every 3 hours for a total of 48 hours after admis-
sion to the intensive care unit. The EDTA plasma was stored at
-70 °G. .:
All parameters were determined within 2 weeks using an ACP
5040 (Eppendorf, D-2000 Hamburg) and commerciälly available
o test reagents for total creatine kinase and isoenzyme MB (immu-
° no-inhibition method), lactate dehydrogenase, a-hydroxybutyrate
dehydrogenase, alanine aminotransferase (EC 2.6.1.2), total and
cytosolic aspartate aminotransferase) 'glutamate dehydrogenase
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(£C 1.4.1.3) catalytic activities, urea and creatinine concentra-
tions. Myoglobin concentration was determined by radioimmu-
noassay using a kit obtained from IDW, Sprendlingen, The acidic
di-glycoprotein concentration was determined by radial immuno-
diffusion using Partigen plates (Behring Institute). Total and cyto-
solic aspartate aminotransferase and alanine aminotransferase as-
say samples were incubated with 233 μπιοΐ/ΐ pyridoxal phosphate
for 15 minutes prior to measurement of enzyme activity.
Human heart mitochondrial aspartate aminotransferase was puri-
fied and antibodies were prepared according to I.e. (16, 17). Cy-
toplasmatic aspartate aminotransferase assay samples (200 μΐ)
were incubated with 233 μιηοΐ/ϊ pyridoxal phosphate and anti-
body solution (70 μΐ), containing the 35—45% ammonium sul-
phate precipitate of rabbit anti human heart mitochondrial aspar-
tate aminotransferase plasma, dialyzed against 0.1 mol/1 triethan-
olamine buffer pH 7.4 (inhibiting 150 U/l of mitochondrial aspar-
tate aminotransferase by 95%) for 30 minutes prior to measure-
ment of activity. Mitochondrial aspartate aminotransferase activi-
ty was calculated from the corresponding total and cytosolic activ-
ities (16). All catalytic activities were determined at 25 °C.
The statistical calculations were carried out using the logarith-
mized values.
Results
The results are presented in table l and figures l—
10. The cytoplasmatic catalytic activities of creatine
kinase, lactate dehydrogenase, a-hydroxybutyrate
dehydrogenase, alanine aminotransferase and aspar-
tate aminotransferase and the concentration of myo-
globin increased at a greater rate and peaked earlier
in the streptokinase treated group. Significantly
higher peak values were found only with the total
creatine kinase catalytic activity and myoglobin cori-
tent, while the mean maximal value was reached sig-
nificantly earlier with creatine kinase and creatine
kinase isoenzyme MB, cytosolic and total aspartate
aminotransferase and lactate dehydrogenase catalyt-
ic activities (U-test from Mann- Whitney and Walter's
asymptotic U-test). All cytoplasmatic proteins mea-
sured, with the exception of alanine aminotransfe-
rase and myoglobin, showed a significant difference
in the course of catalytic activity or concentration in
plasma (two-factorial analysis of variance with re-
peated measures).
Maximal total creatine kinase release was observed
in the heparin group between the 3rd and 6th hour
(76.2 U/l · h) and in the streptokinase treated group
between 1.5 and 3 hours (190 U/l · h). Creatine ki-
nase isoenzyme MB appearance in plasma was grea-
test in the heparin treated group between the 3rd
and 6th hour (8.8 U/l · h) and in the streptokinase
treated group between 1.5 and 3 hours (17.1 U/l ·
h). Myoglobin increase in plasma was greatest be-
tween 0 and 1.5 hours (127.6 μg/l · h in the heparin
group s compared to 191 ng/1 · h in the streptoki-
nase group).
Mitochondrial aspartate aminotransferase activity in
plasma was significantly lower in the streptokinase
treated patients from the 12th to the 39th hour after
admission to the hospital (t-test).
The increase of urea and acidic αι-glycoprotein con-
centrations in plasma was highly significant in both
groups of patients, but there was no difference in the
increase comparing both treatments.
Tab. 1. Data of plasma parameters.
Mean of maximal values
Heparin Strepto-
Creatine kinase











































































































































- no change in course observed, n. s. -=- not significant
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Time of blood sompling [h]
45
Fig. l. Course of plasma catalytic activity of creatine kinase (log
U/l,25 °C, mean value and Standard deviation) of persons
suffering from a myocardial infarction. O—O heparin
treated group, N = 15; Δ Δ streptokinase treated








Time of blood sompting [h]
45
Fig. 2. Course of plasma catalytic activity of creatine kinase
isoenzyme MB (log U/l, 25 °C, mean value and Standard
deviation) of persons suffering from a myocardial infarc-
tion. O—^O heparin treated group, N = 15; Δ Δ
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Fig. 3. Course of plasma catalytic activity of total aspartate ami-
notransferase (log U/l, 25 °C, mean value and Standard
deviation) of persons suffering from a myocardial infarc-
tion. O—O heparin treated group, N = 15; Δ—r-Δ
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Fig. 4. Course of plasma catalytic activity of cytosolic aspartate
aminotransferase (log U/I, 25 °C, mean value and staiU
dard deviation) of persons suffering from a myocardial in^
farction. A<—^Δ heparin treated group, N = 15;O^—0
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Fig. 5. Course of plasma catalytic activity of mitochondrial aspar-
tate aminotransferase (log U/l, 25 °C, mean value and
Standard deviation) of persons suffering from a myocar-
dial infarction. O—O heparin treated group, N = 15;
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Fig. 6. Course of plasma catalytic activity f lactate dehydroge-
nase (log U/l, 25 °C, mean value and Standard deviation)
of persons suffering from a myocardial infarction. O—O
heparin tre ted group, N = 15; Δ-—Δ strept kinase
treated group, N = 18. ' *
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Fig. 7. Course of plasma catalytic activity of a-hydroxybutyrate
dehydrogenase (log U/l, 25 °C, mean value and Standard
deviation) of persons suffering from a myocardial infarc-
tion. O—O heparin treated group, N = 15; Δ Δ
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Fig. 8. Course of plasma concentration of myoglobin (log μg/l,
mean value and Standard deviation) of persons suffering
from a myocardial infarction. O—O heparin treated








Time of blood sompling [h]
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Fig. 9. Course of plasma catalytic activity of alanine aminotrans-
ferase (log U/l, 25 °C, mean value and Standard deviation)
of persons suffering from a myocardial infarction. O—O
heparin treated group, N = 15; Δ-^Δ streptokinase





Time of blood sampling [h]
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Fig. 10. Course of plasma concentration of the acidic arglyco-
protein (log mg/1, mean value and Standard deviation) of
persons suffering from a myocardial infarction. O—O
heparin treated group, N = 15; Δ—-Δ streptokinase
treated group, N = 18.
Discussion
The mortality of patients with acute myocardial in-
farction correlates well with the area of injured myo-
cardium. It is presumed that a zone of ischaemic
tissue surrounds an area of necrosis. The fate of this
border zone determines the progiiosis of the patient
and depends on variqus influences of the infarcted
ventficle (18), although thi$ concept is controversial
(19).
Various therapeutic attempts to limit the size of this
border area and thus to reduce the severity of dam-
age to the myocardi m have been made. These in-
clude most aggressive procedures e.g. acute aorto-
coronary bypass operations or the attempt to estab-
lish coronary reperfusion by angioplasty (catheter
dilatatiqn of the vessel) or intracoronary application
of fibrinolytic drugs. Such procedures, however, are
limited to specialized centers. If the success of in-
travenous therapy with streptokinase could be as-
sured the benefit of thrombolytic treatment could be
extended to a much larger number of patients in-
cluding those in smaller intensive care units where
coronary catherization and angiography are not rou-
tinely available.
Successful intravenous treatment with streptokinase,
i.e. rapid reperfusion of the occluded coronary ar-
tery, has been reported to be correlated with an in-
creased washing-out of cytosolic enzymes from the
ischaemic area, followed by an earlier appearance of
these enzymes in the patient's plasma (20),
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According to this hypothesis one could say that the
thrombolytic therapy of our patients was successful,
if the laboratory results could be supported by clini-
cal data. Total creatine kinase and isoenzyme MB,
total and cytosolic aspartate aminotransferase and
lactate dehydrogenase peak catalytic activities oc-
curred significantly earlier in the streptokinase treat-
ed patients. It is surprising that no such effect could
be seen in myoglobin concentration which contra-
dicts the data of Kaiser et al. (21). At the end of the
study more clinical data will be available, especially
on coronary angiography and scintigraphy, so that a
correlation of accelerated enzyme release into the
patient's plasma with clinical data will be possible.
The kinetics of cytoplasmatic enzyme appearance in
plasma of streptokinase treated patients are in addi-
tion characterized by a more rapid enzyme release
into the plasma, äs indicated by the total creatine ki-
nase catalytic activity (190 U/l · h äs compared to
76.2 U/l · h in the control group). As a result a
higher maximal catalytic activity in plasma and a
higher mean total amount of catalytic activity is ob-
served, at least in the case of creatine kinase isoen-
zymes. This accords well with reports on patients
having received intracoronary streptokinase treat-
ment (22) and data obtained from dogs with reper-
fused and nonreperfused coronary circulation (20).
These results, however, have not been confirmed un-
animously (23).
The difference in course of catalytic activity cannot
be explained by an alteration of enzyme elimination.
In accordance with earlier reports by Anderson et al.
(22) and Kwong et al. (23) we can also demonstrate
that the elimination of the proteins measured is
equal in both groups. As is seen in figures 1—4 and
figure 8, the elimination of plasma catalytic activities
of creatine kinase, creatine kinase isoenzyme MB,
total and cytosolic aspartate aminotransferase and of
concentration of myoglobin is virtually identical for
both groups. It is known that the elimination of en-
zymes from plasma takes place in the reticuloen-
dothelial System during the enzyme transport in the
lymph (24) and that only approximately 15% of en-
zyme catalytic activity released from the myocardial
cells appear in the circulation (25). A consequence
of increased transport of enzymes, e.g. creatine ki-
nase, into the circulation after thrombolysis follow-
ing streptokinase treatment and the unchanged elim-
ination rate in both groups is a decrease of enzyme
inactivation äs indicated by a higher level of enzyme
activity.
A calculation of infarction size for the assessment of
the success of streptokinase treatment based on se-
rial creatine kinase activity values äs proposed by
Shell et al. (26) is not possible if all patients are
placed in one group. The earlier creatine kinase ap-
pearance in plasma would lead to an overestimation
of infarction size in the streptokinase treated group.
Although SheWs approach is probably the best which
is available at present and has evolved considerably
since the initial description (27), alternative ap-
proaches are necessary.
The principles developed by Shell et al. (27) have
been applied to serial measurements of serum myo-
globin concentration (28), but the saine arguments
are valid äs for creatine kinase activity. A definite
answer äs to which enzyme activity is best suited for
calculation of infarction size might be possible when
the enzyme activities and biochemical data obtained
are compared with the recorded ST-segment devia-
tions of the electrocardiograms.
A successful thrombolytic therapy by streptokinase
treatment should result in a decreased infarction size
accompanied by an improved prognosis for the pa-
tient. The appearance of the enzymes priginally lo-
cated in the mitochondria of the muscle cells in the
plasma has been used äs an indicätor of reversible
cellular damage (10, 11). Other parameters, such äs
plasma urea äs an indicätor of prötein break down
(4) and acidic-cti-glycoprotein reflecting the cellular
repairing mechanisms (5) have been used success-
fully for outcome prediction in patients suffering
from acute myocardial infarction (6).
Mitochöndrial aspartate aminotransferase catalytic
activity, acidic arglycoprotein and urea concenträ-
tiöns in plasma were lower in the group which re-
ceived streptokinase treatment, but the differences
were not significant with the exception of mitochon-
drial aspartate aminotransferase catalytic activity be-
tween the 12th and 39th hour after admission of the
patients to the hospital. This could be an indication
of reduction of infarction size, but one has to be
careful to omit the liver äs a source of enzyme activi-
ty, äs it is more slowly perfused during an acute myo-
cardial infarction. In the study, one person (strep-
tokinase group) with a maximum glutamate dehy-
drogenase catalytic activity of 100 U/l was therefore
excluded from the calculations.
The course of mitochondrial aspartate aminotransfe-
rase catalytic activity corresponds to the catalytic ac-
tivity profiles reported in the litefature (9). We de-
tected elevated catalytic activities of-this enzyme in
all patients in the study, which is an indication of im-
proved sensitivity for determinätioii of catalytic con-
centration äs compared to other methöds (29). The
increäse of aspartate aminotraosferase catalytic ac^
tivity from mitochondrial origfti is biphasic with a
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rapid appearance of catalytic activity in plasma until
12 hours after onset of treatment and a slower in-
crease until the end of the study (48 hours). This
characteristic course suggests that necrosis of the
cells after an acute myocardial infarction occurs in
two Steps: rapid, obviously irreversible damage leads
to an appearance of about 40% of maximal enzyme
activity in the plasma and a slowly occurring cellular
necrosis probably reflects the dynamic survival rate
of ischaemic cells surrounding the necrotic area.
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